Galmed Announces Grant of New Use Patents for the combination of Aramchol and Madrigal Pharmaceuticals' Rezdiffra (Resmetirom) for MASH

Core Insights - Galmed Pharmaceuticals has been granted a new Use Patent for its lead compound, Aramchol, covering its combination therapy with Rezdiffra for treating non-alcoholic steatohepatitis (NASH) and liver fibrosis in South Korea [2][3] - The new patent extends Aramchol's patent protection globally until July 2042, reinforcing its position in the NASH/MASH combination therapy market [3] - The patent grant is timely as the industry is increasingly focusing on combination therapies to effectively address NASH/MASH, which has shown limited efficacy with monotherapies [4] Company Overview - Galmed Pharmaceuticals is a clinical-stage biopharmaceutical company specializing in liver, cardiometabolic diseases, and GI oncological therapeutics, with a primary focus on developing Aramchol for liver diseases [5] - The company is actively pursuing opportunities to expand its product pipeline, particularly targeting cardiometabolic indications and innovative drug candidates [5]